Alleviating iatrogenic effects of paclitaxel via antiinflammatory treatment.

ABSTRACT:

Background

Paclitaxel (PTX) is touted as an essential medicine due to its extensive use as a chemotherapeutic agent for various cancers and an antiproliferative agent for endovascular applications. Emerging studies in cardio-oncology implicate various vascular complications of chemotherapeutic agents.

Methods

We evaluated the inflammatory response induced by the systemic administration of PTX. The investigation included RNAseq analysis of primary human endothelial cells (ECs) treated with PTX to identify transcriptional changes in pro-inflammatory mediators. Additionally, we used dexamethasone (DEX), a well-known antiinflammatory compound, to assess its effectiveness in counteracting these PTX-induced changes. Further, we studied the effects of PTX on monocyte chemoattractan

SUBMITTER: Zhang M 

PROVIDER: S-EPMC11365010 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature